Navamedic Asa · OSL:NAVA
Navamedic Asa — Q1 2021 Earnings Presentation
23 slides from Navamedic Asa's earnings presentation, May 2021
Slide 1: First quarter results 2021
Q1 2021 First quarter results 2021 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Q1 2021 highlights
Q1 2021 highlights Growth driven by new products and overall positive performance in underlying portfolio Operations and sales In Q1 2021, revenues grew by 5.4% compared to the same period last year Strong growth for Mysimba®, Alflorex® and ThermaCare® Launched the new and unique UTI product Cystici
Slide 3: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence in all Nordic ~ 30 professionals with Ambitious growth strategy, quality consumer health, countries, Baltics and strong local competence in high-potential pipeline and medical nutrition
Slide 4: Ambition of building a leading Nordic pharma company
Navamedic in brief Ambition of building a leading Nordic pharma company targeting growth in Northern Europe OUR TARGET 1 2 3 20% annual growth STRENGTHEN THE SECURE AND GROWTH THROUGH from 2021 with a mid- CORE INCREASE THE M&A to long-term ambition VALUE THROUGH of building a 500 MNOK company with
Slide 5: Key portfolio developments
KEY PORTFOLIO DEVELOPMENTS @ Navamedic
Slide 6: Key portfolio developments
Key portfolio developments Continued growth for key products in Q1 2021 and Mysimba® and Alflorex® in particular MEDICAL CONSUMER BRANDED SPECIALTY NUTRITION HEALTH GENERICS PHARMA Medical nutrition products for Gastro, pain, urology, other Antibiotics, cardiology, generics Obesity, urology treatmen
Slide 7: Obesity – a global disease with severe health risks
Key portfolio developments Obesity – a global disease with severe health risks 13% OF THE GLOBAL POPULATION World Health Organization (WHO) defines obesity as SUFFER FROM OBESITY abnormal or excessive fat accumulation that presents a Contributing risk factor for diseases such as cardiovascular risk
Slide 8: First obesity treatment of its kind in the Nordics
Key portfolio developments First obesity treatment of its kind in the Nordics – combining medicine and support THE ONLY ORAL MEDICINE FOR TREATMENT OF OBESITY WITH DUAL MODE OF ACTION REDUCES HUNGER AND CRAVINGS & PROVIDES CONTROL OVER FOOD INTAKE KNOWLEDGE BASE AND SUPPORT PROGRAM SUPPLEMENTING OBE
Slide 9: Efforts resulting in increased adoption and traction of Mysimba
Key portfolio developments Efforts resulting in increased adoption and traction of Mysimba® MARKET MARKET STRONG SALES SIZE SHARE DEVELOPMENT Estimated addressable market in the Current market share in the Nordics 24% increase from Q4 20 and 73% Nordic countries (number of people)* and selected coun
Slide 10: Financials
FINANCIALS @ Navamedic
Slide 11: Key consolidated profit and loss figures
Financials Key consolidated profit and loss figures (in NOK '1000) Q1 2021 Q1 2020 Year 2020 Operating revenues 58 644 55 642 209 877 • Revenues increase of 5.4% over Q1 2020 Total revenues 58 644 55 642 209 877 • Strong Gross Profit % due to: Cost of materials -35 432 -39 920 -139 538 Gross profit
Slide 12: Assets
Financials Assets (in NOK '1000) 31.03.2021 31.03.2020 31.12.2020 Assets • Change in Goodwill is due to currency effect Non-current assets • Increase in Other intangible assets is Goodwill 61 121 64 328 64 472 due to the acquisition/booking of the Deferred tax assets 9 168 9 242 9 168 Other intangib
Slide 13: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.03.2021 31.03.2020 31.12.2020 Total equity 145 269 125 542 129 486 Liabilities • Equity ratio of 51.3% Non-current liabilities Non-current license liabilities 6 049 12 746 3 343 • Increase in Equity is mainly due Loans and borrowings 19 526 20 812
Slide 14: Cash flow Group – total operations
Financials Cash flow Group – total operations (in MNOK) Q1 2021 Q1 2020 Year 2020 • The cash flow from Operating Cash flow from operating activities -12,4 -15,3 -3,2 Activities is due to Net profit Cash flow from investing activities 0,0 -1,0 -23,1 coupled with changes in Net Cash flow from financin
Slide 15: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 16: Summary and outlook
Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe In Q1 2021, we have • Strengthened the core by driving underlying growth in the existing portfolio • Launched new consumer health product Cysticina® in Norway • Entered into distribution ag
Slide 17: Q&A
Q&A @ Navamedic
Slide 18: Thank you for your attention!
Thank you for your attention! Navamedic’s half-year and Q2 2021 presentation will be on 13 August 2021
Slide 19: Appendix
APPENDIX @ Navamedic
Slide 20: Condensed consolidated statement of comprehensive income
Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q1 2021 Q1 2020 Year 2020 Operating revenues 58 644 55 642 209 877 Total revenue 58 644 55 642 209 877 Cost of materials -35 432 -39 920 -139 538 Gross profit 23 213 15 722 70 339 Gross profit % 39,6 % 28,3 % 33,5
Slide 21: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q1 2021 Q1 2020 Year 2020 Cash flow from operating activities Profit before tax continuing operations -3 292 -12 166 -16 596 Adjusted for: Depreciation, amortization and impairment 1 341 842 3 659 Financial income / expenses
Slide 22: Basis for preparation and Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 23: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any